ESMO: Mirati’s Adagrasib Appears To Maintain CRC Edge In KRAS Race

 
• By Alaric DeArment
  
Mirati's adagrasib appears to have maintained its edge in the KRAS race • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business